|
BGI Genomics Co., Ltd. (300676.SZ) Évaluation DCF
CN | Healthcare | Medical - Diagnostics & Research | SHZ
|
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
BGI Genomics Co., Ltd. (300676.SZ) Bundle
Évaluez BGI Genomics Co., Ltd. (300676SZ) Perspectives financières comme un expert! Ce calculatrice DCF (300676SZ) vous fournit des données financières pré-remplies et la flexibilité pour modifier la croissance des revenus, le WACC, les marges et autres hypothèses critiques pour s'aligner sur vos projections.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2,800.4 | 8,397.2 | 6,766.1 | 7,046.1 | 4,349.6 | 4,854.7 | 5,418.4 | 6,047.5 | 6,749.7 | 7,533.4 |
| Revenue Growth, % | 0 | 199.86 | -19.42 | 4.14 | -38.27 | 11.61 | 11.61 | 11.61 | 11.61 | 11.61 |
| EBITDA | 600.7 | 2,762.5 | 2,139.5 | 1,560.6 | 643.9 | 1,193.5 | 1,332.1 | 1,486.7 | 1,659.4 | 1,852.0 |
| EBITDA, % | 21.45 | 32.9 | 31.62 | 22.15 | 14.8 | 24.58 | 24.58 | 24.58 | 24.58 | 24.58 |
| Depreciation | 263.8 | 328.2 | 396.4 | 487.7 | 436.8 | 351.0 | 391.8 | 437.3 | 488.0 | 544.7 |
| Depreciation, % | 9.42 | 3.91 | 5.86 | 6.92 | 10.04 | 7.23 | 7.23 | 7.23 | 7.23 | 7.23 |
| EBIT | 336.9 | 2,434.3 | 1,743.1 | 1,072.9 | 207.1 | 842.5 | 940.3 | 1,049.5 | 1,171.3 | 1,307.3 |
| EBIT, % | 12.03 | 28.99 | 25.76 | 15.23 | 4.76 | 17.35 | 17.35 | 17.35 | 17.35 | 17.35 |
| Total Cash | 1,217.5 | 5,430.1 | 8,639.4 | 6,389.7 | 5,486.0 | 3,872.3 | 4,322.0 | 4,823.8 | 5,383.9 | 6,009.0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 1,232.4 | 1,575.7 | 1,244.2 | 2,222.6 | 1,463.7 | 1,421.0 | 1,586.0 | 1,770.2 | 1,975.7 | 2,205.1 |
| Account Receivables, % | 44.01 | 18.76 | 18.39 | 31.54 | 33.65 | 29.27 | 29.27 | 29.27 | 29.27 | 29.27 |
| Inventories | 343.0 | 1,009.8 | 877.7 | 717.8 | 602.2 | 595.0 | 664.0 | 741.1 | 827.2 | 923.3 |
| Inventories, % | 12.25 | 12.03 | 12.97 | 10.19 | 13.84 | 12.26 | 12.26 | 12.26 | 12.26 | 12.26 |
| Accounts Payable | 221.2 | 873.2 | 805.3 | 1,024.9 | 864.6 | 627.4 | 700.3 | 781.6 | 872.3 | 973.6 |
| Accounts Payable, % | 7.9 | 10.4 | 11.9 | 14.55 | 19.88 | 12.92 | 12.92 | 12.92 | 12.92 | 12.92 |
| Capital Expenditure | -626.4 | -301.2 | -383.5 | -1,266.6 | -1,236.4 | -757.6 | -845.5 | -943.7 | -1,053.3 | -1,175.6 |
| Capital Expenditure, % | -22.37 | -3.59 | -5.67 | -17.98 | -28.43 | -15.61 | -15.61 | -15.61 | -15.61 | -15.61 |
| Tax Rate, % | 19.59 | 19.59 | 19.59 | 19.59 | 19.59 | 19.59 | 19.59 | 19.59 | 19.59 | 19.59 |
| EBITAT | 283.6 | 2,083.4 | 1,459.2 | 855.4 | 166.5 | 696.9 | 777.9 | 868.2 | 969.0 | 1,081.5 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -1,433.2 | 1,752.4 | 1,867.8 | -522.6 | 81.3 | 103.1 | 162.9 | 181.8 | 202.9 | 226.4 |
| WACC, % | 8.16 | 8.16 | 8.16 | 8.14 | 8.15 | 8.15 | 8.15 | 8.15 | 8.15 | 8.15 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 679.5 | |||||||||
| Long Term Growth Rate, % | 4.00 | |||||||||
| Free cash flow (T + 1) | 236 | |||||||||
| Terminal Value | 5,669 | |||||||||
| Present Terminal Value | 3,831 | |||||||||
| Enterprise Value | 4,510 | |||||||||
| Net Debt | -4,449 | |||||||||
| Equity Value | 8,959 | |||||||||
| Diluted Shares Outstanding, MM | 412 | |||||||||
| Equity Value Per Share | 21.73 |
What You Will Receive
- Authentic BGI Genomics Data: Comprehensive financials – encompassing revenue to EBIT – derived from real and forecasted figures.
- Complete Customization: Modify all essential parameters (yellow cells) such as WACC, growth percentage, and tax rates.
- Immediate Valuation Adjustments: Automatic recalculations to assess the effects of changes on BGI Genomics’ fair value.
- Flexible Excel Template: Designed for quick modifications, scenario analysis, and in-depth forecasting.
- Efficient and Precise: Avoid starting models from scratch while ensuring accuracy and adaptability.
Key Features
- Authentic BGI Financial Data: Gain access to reliable historical data and future projections specific to BGI Genomics Co., Ltd. (300676SZ).
- Flexible Forecast Options: Modify highlighted cells for key metrics such as WACC, growth rates, and profit margins.
- Automated Calculations: Real-time updates for DCF, Net Present Value (NPV), and cash flow analysis.
- Interactive Dashboard: User-friendly charts and summaries that help visualize valuation outcomes.
- Suitable for All Skill Levels: An intuitive framework designed for investors, CFOs, and consultants alike.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered BGI Genomics data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for BGI Genomics' intrinsic value.
- Step 5: Utilize the outputs for investment decisions or reporting.
Why Choose This Calculator for BGI Genomics Co., Ltd. (300676SZ)?
- User-Friendly Interface: Tailored for both novice users and seasoned professionals.
- Customizable Inputs: Easily adjust parameters to suit your analytical needs.
- Real-Time Updates: Monitor immediate changes in BGI Genomics' valuation as you modify inputs.
- Preconfigured Data: Comes with BGI Genomics' actual financial information for swift evaluations.
- Relied Upon by Experts: Utilized by investors and analysts for making well-informed decisions.
Who Can Benefit from This Product?
- Investors: Accurately assess BGI Genomics' (300676SZ) fair value prior to making investment choices.
- CFOs: Utilize a high-quality DCF model for financial reporting and strategic analysis.
- Consultants: Effortlessly customize the template for client valuation reports.
- Entrepreneurs: Gain valuable insights into financial modeling practices from industry leaders.
- Educators: Employ it as a teaching resource to illustrate various valuation techniques.
Overview of Template Features
- Pre-Filled DCF Model: BGI Genomics’ financial data preloaded for immediate analysis.
- WACC Calculator: Comprehensive calculations for the Weighted Average Cost of Capital.
- Financial Ratios: Assess BGI Genomics’ profitability, leverage, and efficiency metrics.
- Editable Inputs: Modify assumptions such as growth rates, margins, and CAPEX to align with your scenarios.
- Financial Statements: Annual and quarterly reports provided for in-depth analysis.
- Interactive Dashboard: Conveniently visualize essential valuation metrics and outcomes.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.